Latest China News

Astron Corporation has made significant strides in developing its Donald Rare Earths and Mineral Sands Project, securing $14.5 million in funding and progressing towards a Final Investment Decision in 2025 amid key regulatory and operational milestones.

Codeifai Limited reports a sharp 59% reduction in quarterly cash burn alongside a 48% rise in cash receipts, driven by its new ConnectQR SaaS platform and a strategic review of its Material Science division.

Berkeley Energia reports promising lithium and rubidium mineralisation at its Conchas Project while advancing a $1 billion arbitration claim against Spain over regulatory setbacks at Salamanca.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

Nanollose Limited has secured $2.1 million in strategic funding to accelerate the commercialisation of its sustainable fibres and soilless growth technologies, marking a pivotal shift from R&D to market-ready products.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Axel REE Limited reports a breakthrough in its Brazilian exploration with record high-grade rare earth and gallium assays at the Caladão Project, expanding the mineralised area significantly and securing funding to advance resource definition.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Fluence Corporation Limited delivered a standout Q4 2024 with $21.2 million revenue and $1 million EBITDA, driven by a strategic shift to higher-margin Smart Product Solutions. The company’s robust $88 million backlog and $50 million in new orders set the stage for ambitious growth in 2025.

Fluence Corporation delivered a standout Q4 2024 with revenue more than doubling prior quarters, overcoming project delays and market headwinds to set the stage for robust growth in 2025.